Yerevan, Armenia; 1 July, 2015 – FMD K&L Inc., a privately owned contract research organization (CRO) with headquarters in the US and China, recently expanded their operations to Armenia to support their customers’ needs in the region and the growth of their business in Europe.
This office will support client needs for a range of services including study management, data management, biostatistics, programming, clinical data interchange standards consortium (CDISC) compliant eSubmission, medical writing such as protocol development and report writing, monitoring of European clinical sites, and safety handling.
“FMD K&L Inc. has already established their footprint in both the US and China up until this time; however, with our expansive growth potential and ongoing commitment to make ourselves easily accessible to our clients, we felt as though our investment to grow the business in this region was vital and look forward to continued growth in the future,” says Dan Zhang, CEO.
We will be holding a ribbon cutting ceremony at our new offices in Yerevan, Armenia on Friday, 10 July 2015 at 6:30pm. Members of the local government and media are invited to attend. Please plan to arrive between 6:00 – 6:15pm and show press credentials upon arrival. Following the ribbon cutting, members of the executive team will be available to answer questions and take you on a tour of our new facility. Photos and video will be permitted.
“Our initial move into the area has been extremely successful and we have already surpassed our capacity at the current location. We are looking to expand to a larger space in the coming months, growing our staff from 18 to 30 in 2015 and to 60 by the end of 2016,” says Kirit Velani, Client Development Director.
About FMD K&L Inc.
FMD K&L Inc. is a Contract Research Organization (CRO) offering data management, biostatistics, statistical programming, CDISC compliant eSubmission, site monitoring, and medical writing services to the pharmaceutical, biotechnology, and medical device industries worldwide. In addition, we provide regulatory affairs in China and South East Asia, and clinical operations in mainland China, Hong Kong, Taiwan, and South Korea. Our services encompass end-to-end solutions utilizing industry data standards and rigorous operating procedures that enhance our clients’ ability to get their products approved faster, at minimum risk, and lower cost in order to meet patients’ needs for advanced medicines.
# # #